|Mr. Joseph Mannello||CEO & Director||43.36k||N/A||1958|
|Mr. Ren Ren||Global Chairman||N/A||N/A||1962|
|Mr. Joseph DiPietro||Controller||N/A||N/A||N/A|
|Mr. Magshoud Dariani||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Kris Ohrenick||Head of Marketing||N/A||N/A||N/A|
MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of FortetropinÂ on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
MYOS RENS Technology Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.